New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate - film coated tablet - 100 mg - active: ciprofloxacin hydrochloride 116.4mg equivalent to ciprofloxacin 100 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291mg equivalent to ciprofloxacin 250 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 582mg equivalent to ciprofloxacin 500 mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 873mg equivalent to ciprofloxacin 75 0mg, as monohydrate excipient: colloidal silicon dioxide crospovidone hypromellose macrogol 4000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - in adults uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: infections of the lower respiratory tract.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 10 g - oral suspension - 100 mg/ml - active: ciprofloxacin 10 g excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin - oral suspension - 50 mg/ml - active: ciprofloxacin 58.22 mg/ml equivalent to 50 mg/ml ciprofloxacin excipient: hypromellose magnesium stearate methacrylic acid copolymer polysorbate 20 povidone lecithin medium-chain triglycerides purified water strawberry flavour 52312 ah strawberry flavour 54267ah sucrose

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) - solution for infusion - 2 mg/ml - active: ciprofloxacin 2 mg/ml (equates to ciprofloxacin lactate 2.54 mg/ml in the final formulation) excipient: hydrochloric acid lactic acid sodium chloride water for injection - infections of the lower respiratory tract. in the treatment of outpatients with pneumonia due to pneumococcus, ciprofloxacin should not be used as a medicine of first choice. ciprofloxacin can be regarded as a suitable treatment for pneumonias caused by klebsiella, enterobacter, proteus, e. coli, pseudomonas, haemophilus, branhamella, legionella, and staphylococcus.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.